Cambridge Cognition, developer of computerised neuropsychological tests, to go public in the UK

Cam­bridge Cog­ni­tion, one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, just announced its plans to go pub­lic in the UK’s AIM market.

Cam­bridge Cog­ni­tion in £15M AIM IPO (Busi­ness Week­ly): “… the move will val­ue the busi­ness at around £15 mil­lion. It is hoped the shares will be admit­ted to AIM on April 8…The group devel­ops and com­mer­cialis­es com­put­erised neu­ropsy­cho­log­i­cal tests for sale world­wide, prin­ci­pal­ly in the UK – its main coun­try of oper­a­tion – the US and Europe…CCL has two estab­lished prod­uct streams, CANTAB­elect (for clin­i­cal research and tri­als) and CANTABeclipse (for aca­d­e­m­ic and oth­er research)…A third prod­uct, CANTAB­mo­bile, an approved Class II med­ical device, was launched in the UK in May 2012.”

To Learn More:

• News: Cam­bridge Cog­ni­tion in £15M AIM IPO
• Com­pre­hen­sive mar­ket report: The Dig­i­tal Brain Health Mar­ket 2012–2020: Web-based, mobile and bio­met­rics-based tech­nol­ogy to assess, mon­i­tor and enhance cog­ni­tion and brain functioning